Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04973111 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess CT-868 and the Relationship Between Insulin Secretory Response and Ambient Blood Glucose
A Phase 1 study of Diabetes, sponsored by Carmot Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
- 1
- Study location
NCT04973111: Completed Phase 1 study of Diabetes, sponsored by Carmot Therapeutics.
NCT04973111 is a Phase 1 study of Diabetes that has completed, run by Carmot Therapeutics. The registered enrollment target is 32 participants, below the 3,028-participant average among 338 other Diabetes trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04973111, a Phase 1 study of Diabetes, has completed, sponsored by Carmot Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
- 1
- Study location
Study Summary
A Study to Assess the Effect of CT-868 and the Relationship Between Insulin Secretory Response and Ambient Blood Glucose in Obese Male Subjects and Subjects with T2DM.
Conditions Studied
Interventions
- DRUG CT-868 as SC Injection
- DRUG Placebo as SC Injection
- DRUG Active Comparator as SC Injection
Study Locations (1)
California
- Carmot Clinical Research Unit 101 - Chula Vista
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2021-07-16 |
| Est. Completion | 2022-04-22 |
| Phase | Phase 1 |
What the finished NCT04973111 record still lists
NCT04973111 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 3,028-participant average among 338 other Diabetes trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Diabetes appearing as the primary indexed condition, and to 3 interventions - of which CT-868 as SC Injection is the first listed.
NCT04973111 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT04973111 about?
NCT04973111 is a clinical study titled "A Study to Assess CT-868 and the Relationship Between Insulin Secretory Response and Ambient Blood Glucose". A Study to Assess the Effect of CT-868 and the Relationship Between Insulin Secretory Response and Ambient Blood Glucose in Obese Male Subjects and Subjects with T2DM.
What is the current status of trial NCT04973111?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2021-07-16. Estimated completion is 2022-04-22.
What conditions does trial NCT04973111 study?
This clinical trial studies the following conditions: Diabetes.
What interventions are being tested in trial NCT04973111?
The interventions under investigation include: CT-868 as SC Injection (DRUG), Placebo as SC Injection (DRUG), Active Comparator as SC Injection (DRUG).
Who is sponsoring clinical trial NCT04973111?
This trial is sponsored by Carmot Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04973111 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04973111's enrollment target sits among peer trials
32 278th of 338 higher than 60 of 338 other Diabetes trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Mitigating the Pro-inflammatory Phenotype of Obesity
RECRUITING · Phase 1
-
Pancreatic Islet Transplantation Into the Anterior Chamber of the Eye
RECRUITING · Phase 1
-
Insulin Balanced Infusion System
ACTIVE NOT RECRUITING · Phase 1
-
Ability of a Tea Leaf Extracts Preparation to Slow Down Carbohydrate and Fat Absorption
COMPLETED · Phase 1
-
Tissue Penetration of Ceftolozane/Tazobactam in Diabetic Patients With Lower Limb Infections
COMPLETED · Phase 1
-
Family Management of Childhood Diabetes Study
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI